Week in Review: China’s Joinn Labs Buys Major Biopharma Campus in San Francisco
Joinn Laboratories, a China pre-clinical CRO, is the mystery buyer of the ex-Bayer biopharma campus in the San Francisco Bay area; Fosun Pharma, executing its growth-by-acquisition strategy, paid $93 million for a 78% stake in CNS drugmaker Hunan Dongting Pharma; Dahuanong Animal Health paid $25.4 million to purchase 60% of Foshan Standard Bio-tech; GrandPharma of China licensed China rights to Acetium capsules from Biohit Oyj, a Finish drugmaker; China was on the minds of JP Morgan Healthcare Conference attendees, with most companies including a China Strategy in their presentations; China’s government ordered price cuts that averaged 15% on 20 major groups of drugs, affecting many products from international big pharma; Zhifei’s vaccine for TB won SFDA approval to begin a Phase III trial; and EntreMed, a Washington DC-area biotech, filed an application with the SFDA to begin clinical trials of its triple-negative breast cancer treatment. More details…. Stock Symbols: (Xetra: BAY) (SHA: 600196; HK: 2196) (SHE: 300186) (SHE: 300122) (NSDQ: ENMD) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
//-->